Detalhe da pesquisa
1.
Targeting TBK1 to overcome resistance to cancer immunotherapy.
Nature
; 615(7950): 158-167, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634707
2.
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Blood
; 124(3): 420-5, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916506
3.
Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-ß-trap bifunctional antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746510
4.
Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Cancer Cell
; 34(3): 439-452.e6, 2018 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30205046
5.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Cancer Discov
; 8(2): 196-215, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29101162
6.
miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer.
PLoS One
; 8(6): e66502, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23776679
7.
miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer.
Sci Signal
; 4(186): pt5, 2011 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-21868360
8.
TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.
Sci Signal
; 4(177): ra41, 2011 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-21673316
9.
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma.
Sci Transl Med
; 3(74): 74ra22, 2011 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411738
10.
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
J Clin Invest
; 119(5): 1216-29, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19381019